替拉替尼 T6166

Product Introduction
Bioactivity


英文名: Telatinib

描述: Telatinib (Bay 57-9352) 是一种口服具有活力的，小分子的 VEGFR2，VEGFR3，PDGFα 和 c-Kit 抑制剂，它们的 IC50 值分别为6，4，15，1 nM。

体外活性: Telatinib has 0.66, 0.17, and 2.5 times higher IC50 values for VEGFR3, c-Kit, and PDGFRβ than VEGFR2, respectively, while Vatalanib exhibits 18, 20, and 16 times higher IC50 values, respectively, indicating that Telatinib has potential benefit over Vatalanib. Telatinib inhibits VEGFR2 autophosphorylation in a whole-cell assay with an IC50 of 19 nM, suppresses VEGF-dependent proliferation of human umbilical vein endothelial cells with an IC50 of 26 nM, and blocks PDGF-stimulated growth of human aortic smooth muscle cells with an IC50 of 249 nM. [3] Telatinib displays little inhibitory activity against the Raf kinase pathway, epidermal growth factor receptor family, the fibroblast growth factor receptor (FGFR) family, and the Tie-2 receptor. [4]

体内活性: Given that tumor development and metastasis are ascribed to deregulated VEGFR signal pathway, Telatinib treatment significantly inhibits tumor growth and metastasis by blocking the VEGFR signaling and subsequently tumor angiogenesis. In addition to the significant inhibition of tumor angiogenesis, Telatinib treatment induces a significant decrease in endothelium-dependent and endothelium-independent vasodilation, as well as reduction in capillary density, leading to an increase in systolic and diastolic blood pressure. [1] Administration of Telatinib as a single agent exhibits a potent anti-tumor activity in multiple human tumor xenograft models including MDA-MB-231 breast cancer, Colo-205 colon cancer, DLD-1 colon cancer, and H460 non-small cell lung cancer, as well as pancreatic and prostate carcinoma in a dose-dependent manner. [2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 1 mg/mL (2.44 mM)
DMSO : 76 mg/mL (185.4 mM)


关键字: PDGFR | CD117 | c-Kit | Inhibitor | Platelet-derived growth factor receptor | inhibit | Telatinib | VEGFR | Vascular endothelial growth factor receptor | SCFR

相关产品: Ki20227 | VEGFR-2-IN-35 | TG 100572 Hydrochloride | Orantinib | Regorafenib | TG 100801 | Cabozantinib S-malate | SU5408 | PF-03814735 | VEGFR2-IN-1

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Lung Cancer Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library

替拉替尼 T6166信息由TargetMol中国为您提供，如您想了解更多关于替拉替尼 T6166报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途